Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821013 | 0.94 | ALOX12 (0.33) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL4700256 | 0.94 | LMNA (0.30) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL915632 | 0.87 | KMT2A (0.33) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL4394249 | 0.85 | HSD17B10 (0.36) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL2193456 | 0.84 | MEN1 (0.35) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL3959264 | 0.84 | MEN1 (0.30) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL19543529 | 0.83 | MAPK1 (0.37) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL15218253 | 0.83 | ALDH1A1 (0.38) | LMNA | |
| SCHEMBL1747681 | 0.83 | SMN1; SMN2 (0.39) | KMT2AMEN1ATM | |
| SCHEMBL3109277 | 0.83 | GLA (0.33) | KMT2AMEN1LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018115497-A1 | PROTEASOME INHIBITING ß-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | VITA API (FR) | 2018-06-28 | — | — | WO | disclosed |
| EP-2912015-A1 | MIXED INHIBITORS OF AMINOPEPTIDASE N AND OF NEPRILYSINE | Pharmaleads (FR) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014064166-A9 | MIXED INHIBITORS OF AMINOPEPTIDASE N AND OF NEPRILYSINE | PHARMALEADS (FR) | 2015-05-21 | — | — | WO | disclosed |
| WO-2014064166-A1 | MIXED INHIBITORS OF AMINOPEPTIDASE N AND OF NEPRILYSINE | PHARMALEADS (FR) | 2014-05-01 | — | — | WO | disclosed |
| WO-2011091164-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG | XENOPORT, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-7799829-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090192225-A1 | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use | XENOPORT, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-7531572-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090082464-A1 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009033079-A1 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1919859-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | Xenoport, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | XENOPORT, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008013860-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF ALPHA-AMINO ACIDS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20070281996-A1 | Creatine prodrugs, compositions and uses thereof | XENOPORT, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007002013-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192225-A1 | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use | ASNS, ASPH, DNPEP | KMT2A 1398/4885MEN1 2265/4885LMNA 2068/4885 |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | ASNS, ASPH, DNPEP | KMT2A 1398/4885MEN1 2265/4885LMNA 2068/4885 |
| US-20090082464-A1 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | AASDHPPT, ADSL, NAPEPLD | KMT2A 3274/4885MEN1 1261/4885LMNA 2626/4885 |
| US-20070281996-A1 | Creatine prodrugs, compositions and uses thereof | CKMT1A; CKMT1B, PYGM, TNNI3 | KMT2A 2933/4885MEN1 4278/4885LMNA 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.